EMRIS Pharma ^Non-profit

EMRIS Pharma is a company that aims to improve cancer patients' quality of life and treatment compliance by preventing and treating skin toxicities associated with targeted therapies. They are developing a first-in-class solution to block EGFRi monoclonal antibodies topically, which is addressing the skin toxicities induced by EGFR inhibitors (EGFRi) monoclonal antibodies, used as a targeted treatment for advanced colorectal and head and neck cancers. Their innovative approach blocks the initial trigger causing skin toxicity locally without interfering with the cancer treatment. The company's team consists of experienced professionals in biological research, drug development, dermatology, and drug delivery. Contact info: Wadi el-Haj St 13, Nazareth, Israel; lyora@emris-pharma.com.